Jain K, Lam W C, Waheeb S, Thai Q, Heathcote J
Department of Ophthalmology, University Health Network, Toronto Western Hospital, University of Toronto, Ontario, Canada.
Br J Ophthalmol. 2001 Oct;85(10):1171-3. doi: 10.1136/bjo.85.10.1171.
To assess the ocular effect of interferon alfa 2b prescribed with ribavirin in patients undergoing therapy for chronic hepatitis C.
19 patients with chronic hepatitis C who satisfied the follow up criteria were assessed for ocular complications using slit lamp biomicroscopy and indirect ophthalmoscopy before, during, and after the treatment at regular intervals.
8/19 patients, while on treatment, developed an asymptomatic retinopathy. Among these 3/8 were relapsers and 5/9 were non-responders to interferon monotherapy. All retinal changes faded, often while the patients continued the therapy. There was no significant association in occurrence of retinopathy with haematological and/or biochemical changes.
Retinopathy was more common in interferon monotherapy non-responders than relapsers when treated with interferon alfa 2b with the addition of ribavirin. The changes were transient, disappearing while the patients were still being treated.
评估在接受慢性丙型肝炎治疗的患者中，联合利巴韦林使用干扰素α2b的眼部效应。
19例符合随访标准的慢性丙型肝炎患者，在治疗前、治疗期间和治疗后定期使用裂隙灯生物显微镜检查和间接检眼镜检查评估眼部并发症。
19例患者中有8例在治疗期间出现无症状性视网膜病变。其中，8例中的3例为复发者，9例中的5例对干扰素单药治疗无反应。所有视网膜病变均消退，通常在患者继续治疗期间消退。视网膜病变的发生与血液学和/或生化变化无显著关联。
在联合利巴韦林使用干扰素α2b治疗时，视网膜病变在干扰素单药治疗无反应者中比复发者更常见。这些变化是短暂的，在患者仍在接受治疗时消失。
